A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics
Neurodegenerative disorders are primarily characterized by neuron loss. The most common
neurodegenerative disorders include Alzheimer's and Parkinson's disease. Although there …
neurodegenerative disorders include Alzheimer's and Parkinson's disease. Although there …
[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …
affecting around 46 million people worldwide but few treatments are currently available. The …
Pathophysiology of blood–brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and recovery
The blood–brain barrier (BBB) is a dynamic interface responsible for maintaining the central
nervous system homeostasis. Its unique characteristics allow protecting the brain from …
nervous system homeostasis. Its unique characteristics allow protecting the brain from …
Development of polymeric nanoparticles for blood–brain barrier transfer—strategies and challenges
Neurological disorders such as Alzheimer's disease, stroke, and brain cancers are difficult to
treat with current drugs as their delivery efficacy to the brain is severely hampered by the …
treat with current drugs as their delivery efficacy to the brain is severely hampered by the …
[HTML][HTML] Nanotechnology-based drug delivery for central nervous system disorders
Drug delivery to central nervous system (CNS) diseases is very challenging since the
presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier …
presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier …
Self-protecting biomimetic nanozyme for selective and synergistic clearance of peripheral amyloid-β in an Alzheimer's disease model
M Ma, Z Liu, N Gao, Z Pi, X Du, J Ren… - Journal of the American …, 2020 - ACS Publications
Clearance of peripheral amyloid-β (Aβ) has been demonstrated to be promising for
overcoming the blood–brain barrier (BBB) hurdle to eliminate brain-derived Aβ associated …
overcoming the blood–brain barrier (BBB) hurdle to eliminate brain-derived Aβ associated …
Polymeric Nanoparticles for Drug Delivery
The recent emergence of nanomedicine has revolutionized the therapeutic landscape and
necessitated the creation of more sophisticated drug delivery systems. Polymeric …
necessitated the creation of more sophisticated drug delivery systems. Polymeric …
Review of current strategies for delivering Alzheimer's disease drugs across the blood-brain barrier
KH Wong, MK Riaz, Y **e, X Zhang, Q Liu… - International journal of …, 2019 - mdpi.com
Effective therapy for Alzheimer's disease is a major challenge in the pharmaceutical
sciences. There are six FDA approved drugs (eg, donepezil, memantine) that show some …
sciences. There are six FDA approved drugs (eg, donepezil, memantine) that show some …
Impact of nanoparticles on brain health: an up to date overview
Nanoparticles are zero-dimensional nanomaterials and, based on their nature, they can be
categorized into organic, inorganic, and composites nanoparticles. Due to their unique …
categorized into organic, inorganic, and composites nanoparticles. Due to their unique …
Peripheral clearance of brain-derived Aβ in Alzheimer's disease: pathophysiology and therapeutic perspectives
Y Cheng, DY Tian, YJ Wang - Translational neurodegeneration, 2020 - Springer
Alzheimer's disease (AD) is the most common type of dementia, and no disease-modifying
treatments are available to halt or slow its progression. Amyloid-beta (Aβ) is suggested to …
treatments are available to halt or slow its progression. Amyloid-beta (Aβ) is suggested to …